Abstract:Several patients do not benefit from anti-cancer immunotherapies due to resistance for metabolic adaptation and fitness of tumor cells. Highly glycolytic tumor cells outcompete effector T cells for glucose in the tumor microenvironment (TME), impairing T cell function. High levels of lactate dehydrogenase (LDH) correlate with poor prognosis in cancer patients undergoing immunotherapies, inducing aberrant angiogenesis by activating HIF-1α and VEGF expression in endothelial cells (ECs), underscoring a biological interplay between tumor metabolism and neo-angiogenesis that can impact anti-tumor immunity. Main vasculature cells – ECs and pericytes (PCs) – may serve as antigen-presenting cells (APC), influencing T cell responses. While these findings point to a joint metabolic and immune regulation of the vasculature:T-cell crosstalk in the TME, we currently lack a precise understanding of the mechanisms linking tumor metabolism, aberrant angiogenesis, and anti-tumor T-cell responses, and how cell-based therapy may be influence by these factors. We have compared and contrasted vasculature and immune cells phenotypes by high-dimensional flow cytometry in established tumor models representing three major metabolic states by perturbing the two main cellular hubs for producing energy (aerobic glycolysis, by LDHA knock-down; oxidative phosphorylation, by depleting mitochondria as in Rho0 cells) compared to control tumors (NC). We functionally tested the impact of intratumor T cell recruitment according to these phenotypes, by adoptive cell transfer (ACT) therapy using T cells from donor mice immunized with matched-tumor injected i.v. in RAG2 KO mice bearing metabolically-defective tumor (KD or Rho0) and control tumor (NC) in contralateral mammary fat pad. We found that glycolysis-low tumors (LDH-A KD) show a better vasculature with reduced proportions of angiogenic activated PCs (cluster1: NG2+PDGFRbneg) and increased frequencies of "stabilizing" PCs (cluster 2: NG2negPDGFRb+, which counteract the formation of leaky vessels), compared to NC. However, KD tumors also display a reduction in MECA-79+ high endothelial venules. Moreover, LDHA-KD vs. NC tumors displayed ECs and cluster 2 PCs with greater expression of MHCI and decreased expression of FAS-L, and more EC expressing MHCII or PD-L1. In addition, the immune infiltrate of KD tumors is characterized by increased amounts of T effector cells and lower amounts of Gr1-low myeloid derived suppressor cells (MDSCs). The changes in vascularization phenotype have been confirmed in RAG2 KO mice bearing bilateral tumor variants model. ACT in these mice bearing bilateral 4T1-NC and -KD tumors resulted in greater biodistribution of T cells in the KD tumors, showing decreasing tumor growth. Vasculature features correspond to greater intratumor T-cell trafficking, indicating a mechanistic link between tumor glycolysis, aberrant angiogenesis, and T-cell exclusion. This would aim to elucidate the mechanisms through which these processes are connected for developing more efficacious T-cell-targeted therapies. Citation Format: Giorgia Colombo, Jee Hye Kang, Inna Serganova, Roberta Zappasodi. Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B049.

Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models

Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells

Engineering ROS‐Responsive Bioscaffolds for Disrupting Myeloid Cell‐Driven Immunosuppressive Niche to Enhance PD‐L1 Blockade‐Based Postablative Immunotherapy

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

Abstract B049: Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity

Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

Pericytes: jack-of-all-trades in cancer-related inflammation

Cellular-level Phenotyping of Tumor-Immune Microenvironment (time) in Patients in Vivo Reveals Distinct Inflammation and Endothelial Anergy Signatures

Enhanced tumor response to adoptive T cell therapy with PHD2/3-deficient CD8 T cells

Hexokinase 2-Driven Glycolysis in Pericytes Activates Their Contractility Leading to Tumor Blood Vessel Abnormalities

Combinational Therapy of Interferon-Α and Chemotherapy Normalizes Tumor Vasculature by Regulating Pericytes Including the Novel Marker RGS5 in Melanoma.

In Vitro Vascularized Immunocompetent Patient-Derived Model to Test Cancer Therapies.

Alleviating Tumor Hypoxia and Immunosuppression Via Sononeoperfusion: A New Ally for Potentiating Anti-Pd-l1 Blockade of Solid Tumor

Predicting prognosis and immunotherapy response in colorectal cancer by pericytes insights from single-cell RNA sequencing

Phosphatidylserine Targeting Antibody Enhances Anti-Tumor Activity Of Adoptive Cell Therapies In A Mouse Melanoma Model

Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy

Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade

Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

Alleviating hypoxia to improve cancer immunotherapy

Abstract 5389: Development of T-cell exclusion in melanoma

Pericytes require physiological oxygen tension to maintain phenotypic fidelity.